南方医科大学学报2011，Vol.31Issue(8)：1458-1460,3.
曲妥珠单抗联合FOLFIRI治疗HER2阳性晚期胃癌的疗效观察
Efficacy of trsatuzumab (Herceptin) combined with FOLFIRI regimen in the treatment of HER2-positive advanced gastric cancer
孙杰 1潘赛英 1陈倩琪 1高小平 1李伟1
作者信息
- 1. 广东医学院附属南山医院肿瘤内科,广东深圳518052
- 折叠
摘要
Abstract
Objective To evaluate the safety and efficacy of trsatuzumab (Herceptin) combined with FOLFIRI regimen (irinotecan plus 5-FU/LV) in the treatment of HER2-positive advanced gastric cancer. Methods Thirty-four patients with pathologically confirmed advanced gastric cancer, all positive for the human epidermal growth factor receptor 2 (HER2) as identified by immunohistochemistry and fluorescence in situ hybridization, were randomized into the test group and control group to for treatment with the combined regimen and the FOLFIRI regimen alone, respectively. FOLFIRI regimen was administered every 2 weeks for 2 to 4 cycles. Trsatuzumab was given intravenously on a weekly basis with an initial dose of 4 mg/kg and a subsequent dose of 1 fng/kg: All the patients were assessed for efficacy and toxicity of the treatments. Results The overall response rate Was 58.8% in the test group and 35.3% in the control group, with disease control rates of 88.2% and 64.7%, respectively, showing significant differences between the two groups (P<0.05). The most frequent grade I/II treatment-related adverse events included diarrhea, nausea/vomiting and neutropenia. Conclusion Trsatuzumab combined with FOLFIRI regimen is effective, safe and well tolerated for treatment of HER2-positive advanced gastric cancer.关键词
曲妥珠单抗/伊立替康/氟尿嘧啶/胃癌/HER-2/neuKey words
trsatuzumab/ irinotecan/ fluorouracil/ gastric cancer/ HER-2/neu分类
医药卫生引用本文复制引用
孙杰,潘赛英,陈倩琪,高小平,李伟..曲妥珠单抗联合FOLFIRI治疗HER2阳性晚期胃癌的疗效观察[J].南方医科大学学报,2011,31(8):1458-1460,3.
